首页> 外文期刊>The journal of clinical psychiatry >The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2003 Update.
【24h】

The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2003 Update.

机译:德州药物治疗算法项目精神分裂症抗精神病算法:2003年更新。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: The Texas Medication Algorithm Project (TMAP) has been a public-academic collaboration in which guidelines for medication treatment of schizophrenia, bipolar disorder, and major depressive disorder were used in selected public outpatient clinics in Texas. Subsequently, these algorithms were implemented throughout Texas and are being used in other states. Guidelines require updating when significant new evidence emerges; the antipsychotic algorithm for schizophrenia was last updated in 1999. This article reports the recommendations developed in 2002 and 2003 by a group of experts, clinicians, and administrators. METHOD: A conference in January 2002 began the update process. Before the conference, experts in the pharmacologic treatment of schizophrenia, clinicians, and administrators reviewed literature topics and prepared presentations. Topics included ziprasidone's inclusion in the algorithm, the number of antipsychotics tried before clozapine, and the role of first generation antipsychotics. Data were rated according to Agency for Healthcare Research and Quality criteria. After discussing the presentations, conference attendees arrived at consensus recommendations. Consideration of aripiprazole's inclusion was subsequently handled by electronic communications. RESULTS: The antipsychotic algorithm for schizophrenia was updated to include ziprasidone and aripiprazole among the first-line agents. Relative to the prior algorithm, the number of stages before clozapine was reduced. First generation antipsychotics were included but not as first-line choices. For patients refusing or not responding to clozapine and clozapine augmentation, preference was given to trying monotherapy with another antipsychotic before resorting to antipsychotic combinations. CONCLUSION: Consensus on algorithm revisions was achieved, but only further well-controlled research will answer many key questions about sequence and type of medication treatments of schizophrenia.
机译:背景:德克萨斯药物治疗算法项目(TMAP)是一项公共-学术合作,其中在德克萨斯州选定的公共门诊使用了精神分裂症,躁郁症和重度抑郁症的药物治疗指南。随后,这些算法在整个德克萨斯州实施,并在其他州使用。准则要求在出现大量新证据时进行更新;精神分裂症的抗精神病算法最近一次更新是在1999年。本文报告了由专家,临床医生和管理人员组成的小组在2002年和2003年提出的建议。方法:2002年1月的一次会议开始了更新过程。会议之前,精神分裂症的药物治疗专家,临床医生和管理人员审阅了文献主题并准备了演讲。主题包括齐拉西酮纳入算法,在氯氮平之前尝试使用的抗精神病药数量以及第一代抗精神病药的作用。根据医疗保健研究机构和质量标准对数据进行评级。在讨论了演示文稿之后,会议与会者得出了共识建议。随后考虑通过电子通讯处理阿立哌唑的纳入问题。结果:精神分裂症的抗精神病药算法已更新,包括一线药物中包括齐拉西酮和阿立哌唑。相对于先前的算法,氯氮平之前的阶段数减少了。包括第一代抗精神病药,但不作为一线选择。对于拒绝或不响应氯氮平和氯氮平增强的患者,在采取抗精神病药物组合之前,首选尝试与另一种抗精神病药物进行单药治疗。结论:已达成算法修订的共识,但只有进一步良好控制的研究才能回答有关精神分裂症药物治疗的顺序和类型的许多关键问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号